One To Watch
Ridgeback Biotherapeutics
Company Overview
A Miami-based private biotechnology company developing treatments for emerging and serious infectious diseases, best known for EBANGA, its FDA-approved Ebola monoclonal antibody, and co-developing molnupiravir (Lagevrio) with Merck for COVID-19. Ridgeback describes itself as guided by patient outcomes rather than profitability, a posture that informs its focus on neglected and outbreak-driven conditions. The company holds two approved products and two preclinical candidates in its pipeline.
Headquarters and Global Presence
Ridgeback Biotherapeutics is headquartered in Miami, Florida. Its commercial and development footprint extends internationally through its partnership with Merck for Lagevrio and through its manufacturing agreement with Emergent BioSolutions for EBANGA.
Founding and History
Ridgeback was founded in 2016 by Wendy Holman and Wayne Holman. In 2018 the company in-licensed the monoclonal antibody mAb114 from the National Institute of Allergy and Infectious Diseases (NIAID), which ultimately became the FDA-approved EBANGA. In early 2020, Ridgeback acquired an exclusive worldwide license to molnupiravir (EIDD-2801) from Emory University's not-for-profit Drug Innovation Ventures at Emory (DRIVE), a compound developed with approximately $16 million in US federal grant funding. The subsequent Merck partnership and dual approvals within five years of licensing each asset mark a rapid commercial trajectory for a young private company.
Therapy Areas and Focus
Ridgeback is focused exclusively on emerging and serious infectious diseases, targeting pathogens where therapeutic options are scarce or absent at the time of outbreak. Its approved assets address Ebola virus disease and COVID-19, two conditions that defined major global health crises over the last decade. Preclinical programs RB-1569 and RB-3142 continue to expand the company's emerging infectious disease portfolio. The company's model — sourcing externally discovered compounds and advancing them rapidly through partnerships — is tailored to respond to urgent unmet need.
Technology Platforms and Modalities
Ridgeback's pipeline spans two distinct modalities. EBANGA is a human monoclonal antibody that neutralizes the Zaire ebolavirus by targeting the viral glycoprotein, blocking host cell entry. Molnupiravir is an oral nucleoside analogue that acts as a ribonucleoside analogue, inducing error catastrophe in RNA viruses including SARS-CoV-2 through viral RNA polymerase incorporation. The combination of antibody and small-molecule antiviral expertise positions Ridgeback to address a broad range of RNA viral threats.
Key Pipeline and Programs
EBANGA (ansuvimab-zykl, formerly mAb114) is a human monoclonal antibody approved by the US FDA in December 2020 for the treatment of Ebola virus disease caused by Zaire ebolavirus in adults and pediatric patients. Originally licensed from NIAID in 2018, the antibody was evaluated during Ebola outbreaks in the Democratic Republic of the Congo, where several hundred patients received treatment. Manufacturing and commercialization are supported through an agreement with Emergent BioSolutions signed in 2022.
Molnupiravir (Lagevrio, MK-4482, EIDD-2801) is an oral antiviral nucleoside analogue co-developed with Merck for mild-to-moderate COVID-19 in high-risk adults. It received US FDA Emergency Use Authorization in December 2021 and was evaluated in the Phase III MOVe-OUT and MOVe-NOW trials. Merck leads worldwide development and commercialization under a partnership established in 2020.
RB-1569 and RB-3142 are two preclinical candidates in development for emerging infectious diseases. Full target indications and mechanisms have not been publicly disclosed, but both sit within Ridgeback's core focus on high-priority outbreak pathogens.
Recent Developments
The WHO declared an Ebola outbreak a global health emergency, renewing attention on EBANGA as a frontline therapeutic option and underlining the continued strategic importance of Ridgeback's antibody franchise. Ridgeback's in-license of mAb114 from NIAID, originally signed in 2018, was covered by The Pharma Letter as a notable early step in the company's infectious disease build-out. Molnupiravir's EUA in December 2021 and its subsequent commercial rollout with Merck remain the company's highest-profile regulatory achievement to date. No major new pipeline announcements or funding events have been publicly reported in the most recent six-month window.
Key Personnel
Wendy Holman serves as Co-Founder and Chief Executive Officer. She has led Ridgeback since its founding in 2016, overseeing the licensing, development, and approval of both EBANGA and Lagevrio within a six-year period. Wayne Holman serves as Co-Founder and is also the founder of Ridgeback Capital Management, bringing investment and capital allocation expertise to the company's strategic direction.
Strategic Partnerships
Ridgeback's most significant collaboration is its worldwide partnership with Merck for the development and commercialization of molnupiravir/Lagevrio, established in 2020. EBANGA's commercial supply chain is supported through a manufacturing and commercialization agreement with Emergent BioSolutions entered in 2022. Both EBANGA and molnupiravir were externally sourced — from NIAID and Emory University respectively — reflecting Ridgeback's strategy of in-licensing advanced scientific assets and scaling them through established partners.
FAQ Section
Ridgeback explicitly prioritizes patient outcomes over profitability, targeting emerging infectious diseases where commercial interest is low but medical need is acute. This model depends on rapid in-licensing of externally discovered assets — from institutions like NIAID and Emory University — and pairing them with large partners such as Merck for commercialization at scale. The strategy has already produced two approved products in under six years, a striking track record for a private company of its size.
Ebola virus disease, caused by Zaire ebolavirus, carries case fatality rates of up to 90% in some outbreaks and continues to generate sporadic but severe public health emergencies, as recent WHO declarations confirm. EBANGA works by binding the viral glycoprotein on the surface of the ebolavirus, blocking the entry mechanism the virus uses to infect host cells. Its origin in clinical use during the DRC outbreaks — with several hundred patients treated — provides a real-world evidence base unusual for therapies targeting rare emerging pathogens.
Molnupiravir is an oral nucleoside analogue that induces error catastrophe in RNA viruses, distinguishing it mechanistically from protease inhibitors such as nirmatrelvir/ritonavir (Paxlovid). It was the first oral COVID-19 antiviral to receive FDA Emergency Use Authorization, in December 2021. Ridgeback holds rights through its license from Emory University's DRIVE and shares worldwide development and commercialization responsibilities with Merck, which leads the commercial effort under the Lagevrio brand.
EBANGA received full FDA approval in December 2020 for treatment of Ebola virus disease caused by Zaire ebolavirus in adults and pediatric patients — one of only a handful of approved Ebola therapeutics. The antibody was evaluated in clinical settings during Ebola outbreaks in the Democratic Republic of the Congo, where real-world use in several hundred patients informed the approval. Manufacturing is handled through Ridgeback's agreement with Emergent BioSolutions, supporting supply readiness for future outbreak response.
Beyond EBANGA and Lagevrio, Ridgeback is advancing two preclinical candidates, RB-1569 and RB-3142, both targeting emerging infectious diseases. The company's pipeline logic is consistent: identify high-priority outbreak pathogens where no approved therapy exists, source innovative compounds, and move them forward under a public-health-oriented mandate. This focus keeps Ridgeback in the narrow but strategically important space of biodefense-adjacent infectious disease therapeutics.
Ridgeback is in a post-approval, pipeline-building phase, having achieved FDA approvals for both of its lead assets by late 2021. The company remains privately held with no announced plans for an IPO, relying on partnership revenues and its founders' backing from Ridgeback Capital Management. Near-term attention centers on the continued commercial performance of Lagevrio with Merck, EBANGA's deployment in active Ebola outbreaks, and any IND-enabling progress on RB-1569 and RB-3142.
The principal watchpoints for Ridgeback over the next 12-24 months include:
- Lagevrio commercial trajectory: Ongoing Merck sales data and any label updates or new indication filings for molnupiravir as COVID-19 treatment patterns evolve.
- EBANGA outbreak deployment: WHO or national emergency declarations triggering procurement and use of EBANGA in the field, with the most recent global emergency declaration heightening near-term relevance.
- Preclinical pipeline advancement: IND filings or Phase I entry for RB-1569 and RB-3142 would signal the next wave of pipeline value creation.
- Partnership and licensing activity: Given its in-licensing model, any new asset acquisitions from NIAID, academic institutions, or government-backed programs would be a significant signal.
- Private company opacity: As a closely held firm, Ridgeback discloses limited financial and operational data, making pipeline progress harder to track than for publicly listed peers.
Latest Ridgeback Biotherapeutics News
Today's issue
| Headless Content Management with Blaze